

services and career, retirement and benefits counseling. Serves as ACF liaison to the Department on all payroll matters. Provides the following personnel administrative services: the exercise of appointing authority, position classification, awards authorization, personnel management evaluation, personnel action processing and recordkeeping. Manages the merit promotion, special hiring and placement programs. Provides leadership in directing and managing agency-wide staff development and training activities for ACF.

The Office provides leadership, oversight, and coordination for the planning, analysis, and development of human resource policies and programs. Serves as liaison between ACF, the Department, and the Office of Personnel Management. Provides technical advice and assistance on policy, legal and regulatory matters. Formulates and interprets policies pertaining to all areas related to personnel administration and management. Formulates and interprets new human resource programs and strategies.

Formulates and oversees the implementation of ACF-wide policies, regulations and procedures concerning all aspects of the Senior Executive Service (SES), and SES equivalent recruitment, staffing, position establishment, compensation, award, performance management and other related personnel areas. Manages the performance recognition systems and the responsibilities of the Executive Resources Board (ERB) and the Performance Review Board (PRB). Coordinates the Schedule C and Executive personnel activity with the Office of the Secretary. Is the focal point for data, reports, and analyses relating to SES, Schedule C and other executive personnel, such as those in Executive Level positions.

Provides management advisory service on all labor management and employee relations issues. Plans and coordinates ACF-wide employee relations and labor relations activities, including the application and interpretation of the Federal Labor-Management Relations Program, collective bargaining agreements, disciplinary and adverse action regulations, and appeals. Pursues human relations innovations such as alternative dispute resolutions and serves as the focal point in all issues pertaining to the Labor-Management Partnership Council. Provides leadership in assuring the integrity, effectiveness and impartiality of ACF's alternative dispute resolution programs, grievances, and merit systems program. Participates in the formulation and

implementation of policies, practices and matters affecting bargaining unit employees' working conditions by assuring management's compliance with the Federal Labor Relations Program (5 U.S.C. Chapter 71).

Administers ACF's personnel security responsibilities and ethics program. Coordinates the ethics program with the Department's Office of Special Counsel for Ethics.

The Office is responsible for the functional management of all program, common needs and management training in the agency, including policy development, guidance, and technical assistance and evaluation of aspects of program, career, employee, supervisory, management and executive training. Provides leadership in implementing the recommendations of the Staff Development and Training Team by managing/overseeing and monitoring the ACF Training Resource Center and institutionalizing long-term development training for ACF employees. Supports the daily work and special projects of ACF employees by managing for Information Resource Center (library).

e. Delete Paragraph K in its entirety.

Dated: December 3, 1998.

Elizabeth M. James,

Deputy Assistant Secretary for Administration.

[FR Doc. 98-33324 Filed 12-15-98; 8:45 am]

BILLING CODE 4184-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Anesthetic and Life Support Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Anesthetic and Life Support Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on January 12, 1999, 9 a.m. to 5 p.m.

Location: FDA Bldg. 5630, conference room, 5630 Fishers Lane, Rockville, MD.

Contact Person: Karen M. Templeton-Somers, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane,

301-827-7001, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12529. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will hear presentations and discuss the cardiovascular safety data submitted regarding new drug application (NDA) 20-997, Chirocaine™ (levobupivacaine injection), Darwin Discovery Ltd., a local anesthetic agent indicated for surgical anesthesia and pain management.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 5, 1999. Oral presentations from the public will be scheduled between approximately 9:15 a.m. and 9:45 a.m. and between 1:15 p.m. and 1:45 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before January 5, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: December 8, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98-33291 Filed 12-15-98; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Oncologic Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Oncologic Drugs Advisory Committee.

General Function of the Committee:

To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on January 12, 1999, 8:30 a.m. to 5:30 p.m., and January 13, 1999, 8 a.m. to 5 p.m.

Location: Holiday Inn, Walker/Whetstone Rooms, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Karen M. Templeton-Somers, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12542. Please call the Information Line for up-to-date information on this meeting.

Agenda: On January 12, 1999, the committee will discuss: (1) New drug application (NDA) 21-029, Temodal® (temozolomide) Capsules, Schering Corp., indicated for the treatment of adult patients with malignant glioma (glioblastoma multiforme and anaplastic astrocytoma) at first relapse, and (2) NDA 50-766 Prograf® (tacrolimus) capsules, 1 milligram (mg) and 5 mg, and Prograf (tacrolimus) injection 5 mg (for IV infusion only), Fujisawa Healthcare, Inc., indicated for the prophylaxis of graft-versus-host disease in patients receiving allogeneic bone marrow transplants. On January 13, 1999, the committee will discuss: (1) NDA 20-954 Busulfex™ (busulfan) Injection, Orphan Medical, Inc., indicated for use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation. Diseases in which patient benefit from this mode of therapy has been demonstrated include acute lymphocytic leukemia, acute nonlymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, non-Hodgkins lymphoma, Hodgkins disease, multiple myeloma, myelodysplastic syndrome, breast cancer, ovarian cancer, and genetic diseases, and (2) NDA 20-765 OraTest™ (tolonium chloride), Zila, Inc., an oral rinse that is indicated for use as a diagnostic adjunct in patients with oral lesions suspected or known to be malignant, to help in detection of all sites of cancer, definition of borders or cancerous lesions, and selection of sites to be biopsied.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 4, 1999. Oral presentations from the public will be scheduled between approximately 8:45 a.m. and 9 a.m., and 1:45 p.m. and 2

p.m. on January 12, 1999; and between approximately 8:15 a.m. and 8:30 a.m., and 1:15 p.m. and 1:30 p.m. on January 13, 1999. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before January 4, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. After the scientific presentations, a 30-minute open public session will be conducted for interested persons, who have submitted their request to speak by January 4, 1999, to address issues specific to the submission or topic before the committee.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: December 8, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98-33290 Filed 12-15-98; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Indian Health Service

Health Professions Preparatory, Pregraduate and Indian Health Professions Scholarship Programs

AGENCY: Indian Health Service, HHS.

ACTION: Update of Standing Notice of Availability of Funds for Health Professions Preparatory, Pregraduate and Indian Health Professions Scholarship Programs published in 62 FR 5443, February 5, 1997.

SUMMARY: The Indian Health Service (IHS) announces the availability of approximately \$3,578,200 to fund scholarships for the Health Professions Preparatory and Pregraduate Scholarship Programs for FY 1999 awards. These programs are authorized by section 103 of the Indian Health Care Improvement Act (IHCIA), Pub. L. 94-437, as amended by Pub. L. 100-713, Pub. L. 102-573, and by Pub. L. 104-313. The Indian Health Scholarship (Professions) authorized by section 104 of the IHCIA, Pub. L. 94-437, as amended by Pub. L. 100-713, Pub. L. 102-573, and by Pub. L. 104-313, has approximately \$7,636,100 available for FY 1999 awards.

Part-time and full-time scholarships will be funded for each of the three

scholarship programs for the academic year 1999-2000.

The Health Professions Preparatory Scholarship Grant Program is listed as No. 93.123 in the Office of Management and Budget Catalog of Federal Domestic Assistance (CFDA). The Health Professions Pregraduate Scholarship Grant Program is listed as No. 93.971, and the Indian Health Professions Scholarship Grant Program is listed as No. 93.972 in the CFDA.

DATES: The application deadline for new applicants is April 15, 1999. The application deadline for continuation applicants is April 1, 1999. Applications shall be considered as meeting the deadline if they are received by the appropriate Scholarship Coordinator on the deadline date or postmarked on or before the deadline date. (Applicants should request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a commercial carrier or U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.)

APPLICATIONS: New applicants applying for Scholarships under the three programs must utilize the forms contained in the "Application for Participation in the IHS Scholarship Program", (OMB No. 0917-0006, 04/30/2001). Application packets may be obtained by calling or writing to the addresses listed below.

FOR FURTHER INFORMATION CONTACT: Please address application inquiries to the appropriate Indian Health Service Area Scholarship Coordinator, as listed below.

IHS Area Office Scholarship Coordinator/and States/Locality Served:

Aberdeen Area IHS: Ms. Lila Jean Topalian, Scholarship Coordinator, IHS Aberdeen Area, Federal Building, Room 309, 115 4th Avenue, SE., Aberdeen, SD 57401
Tele: 605-226-7553

Iowa
Nebraska
North Dakota
South Dakota

Alaska Area Native Health Service: Ms. Rose Jerue, Scholarship Coordinator, IHS Alaska Area, 4141 Ambassador Drive, Rm. 349, Anchorage, Alaska 99508, Tele: 907-729-1332

Alaska

Albuquerque Area IHS: Ms. Alvina Waseta, Scholarship Coordinator, IHS Albuquerque Area, 5300 Homestead Road, NE, Albuquerque, NM 87110, Tele: 505-248-4513
Colorado
New Mexico